Telix director Maria Rivas files initial Form 3

Telix Pharmaceuticals Ltd filed an initial Form 3 for board member Maria Rivas.

Accepted by SEC EDGAR 05/18/2026 - 06:31 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Telix Pharmaceuticals Ltd filed an initial Form 3 for board member Maria Rivas. This filing establishes her status as a director and provides a baseline disclosure of her beneficial ownership as an insider. The data provided shows no reported purchases, sales, exercises, gifts, or other equity transactions.

Key Terms

Form 3, reportingPersons, ten percent owner

3 terms

Form 3 regulatory

"INSIDER FILING DATA (Form 3)"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

reportingPersons regulatory

""reportingPersons": [{"name": "Rivas Maria""

ten percent owner financial

""is_ten_percent_owner": 0"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Telix Pharmaceuticals (TLX) Form 3 for Maria Rivas show?

The Form 3 records Maria Rivas as a director of Telix Pharmaceuticals Ltd and establishes her initial beneficial ownership position as an insider. The summarized data shows no reported purchases, sales, exercises, gifts, or other equity transactions in this filing.

Did Maria Rivas buy or sell Telix Pharmaceuticals (TLX) shares in this Form 3?

No transactions are indicated in the summarized data for this Form 3. The buy, sell, exercise, gift, tax withholding, and restructuring counts and share totals are all shown as zero, suggesting this filing focuses on initial ownership disclosure rather than trading activity.

What insider role does Maria Rivas hold at Telix Pharmaceuticals (TLX)?

The filing identifies Maria Rivas as a director of Telix Pharmaceuticals Ltd. She is not marked as an officer and is not classified as a ten percent owner in the structured data, clarifying the capacity in which she is considered an insider.

Does the Telix Pharmaceuticals (TLX) Form 3 indicate option or derivative positions?

The derivative-related fields in the summarized data are all zero, and the derivativeSummary list is empty. This indicates that no options, warrants, or other derivative securities are reported for Maria Rivas in this specific Form 3 submission.

Is there any Rule 10b5-1 trading plan mentioned in the Telix (TLX) Form 3?

The provided data does not include any footnote text referencing a Rule 10b5-1 trading plan. Footnotes can describe pre-arranged trading, but in this case the footnote field is effectively empty, so no such plan is indicated in the excerpt.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Rivas Maria

(Last) (First) (Middle)

C/O TELIX PHARMACEUTICALS LTD

55 FLEMINGTON RD

(Street)

NORTH MELBOURNE 3051

(City) (State) (Zip)

AUSTRALIA

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
05/11/2026

3. Issuer Name and Ticker or Trading Symbol
Telix Pharmaceuticals Ltd [ TLX ]

3a. Foreign Trading Symbol
[TLX]

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Ex. 24 - Power of Attorney

No securities are beneficially owned.

	/s/ Oliver Newman, on behalf of Maria Rivas	05/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)